Durvalumab is an anti-PD-L1 monoclonal antibody, humanized.Durvalumab completely blocked the binding of PD-L1 to PD-1 and CD80, and the IC50s were 0.1 and 0.04 nM, respectively.

[accordions]
[accordion title= “Targets&IC50“]

PD-L1/PD-1:0.1 nM , PD-L1/CD80:0.04 nM

[/accordion]

[accordions]
[accordion title= “In vivo“]

Durvalumab inhibits tumor growth in a mouse xenograft model of human melanoma (A375) and pancreatic (HPAC) tumor cell lines through a T-cell-mediated mechanism.The tumor growth inhibition of HPAC cells was 74% and that of A375 cells was 77%.Durvalumab had no effect on the growth of the A375 xenograft tumor in the absence of T cells.

[/accordion]

[accordions]
[accordion title= “References and Literature“]

1. Faiena I, et al. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. Drug Des Devel Ther. 2018 Jan 23;12:209-215.2. Stewart R, et al. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer Immunol Res. 2015 Sep;3(9):1052-62.

[/accordion]

[accordions]
[accordion title= “Chemical Properties“]

[/accordion]